AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMURON LTD

0.062

-0.002-3.12%

Volume:150.28K

Turnover:9.32K

Market Cap:14.48M

PE:-1.92

High:0.062

Open:0.062

Low:0.062

Close:0.064

Loading ...

Overview Company News Filings

BRIEF-Immuron Travelan Highest Sales In History

Immuron Travelan® Highest Sales in History

THOMSON REUTERS

Immuron Posts Above AU$5 Million Revenue for Nine Months to March, Shares Up 12%

MT Newswires Live

BUZZ-Australia's Immuron gains on highest annual sales for its Travelan drug

Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%

MT Newswires Live

BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand

Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs

THOMSON REUTERS

BRIEF-Immuron Travelan® continued strong sales growth

Immuron Travelan® Continued Strong Sales Growth

THOMSON REUTERS

Immuron's Global Sales for Travelan Surge 249% in December 2024 Quarter; Shares Rise 8%

MT Newswires Live

Immuron Partners With Monash University on Antimicrobial Resistance Research; Shares Down 12%

MT Newswires Live

BRIEF-Immuron Announces Travelan® Clinical Trial Update

Immuron Announces Travelan® Clinical Trial Update

THOMSON REUTERS

Immuron progresses development of traveller’s diarrhea drug Travelan

The Market Herald

BUZZ-Australia's Immuron rises on positive results for Travelan Phase 2 study

Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th

Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th

Immuron Travelan® Continued Strong Sales Growth

THOMSON REUTERS

Immuron's Travelan Sales Climb 13% in September Quarter; Shares Up 4%

MT Newswires Live

BRIEF-Immuron Posts Quarterly Global Sales A$1.5 Million, Up 13% On Prior Quarter

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMC.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMC.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","market":"AU","secType":"STK","nameCN":"IMMURON LTD","latestPrice":0.062,"timestamp":1745302320000,"preClose":0.064,"halted":0,"volume":150282,"delay":0,"nameEN":"IMMURON LTD","floatShares":200499327,"shares":233526869,"eps":-0.032226,"marketStatus":"Not Yet Opened","change":-0.002,"latestTime":"04-22 16:12:00 AEST","open":0.062,"high":0.062,"low":0.062,"amount":9317,"amplitude":0,"askPrice":0.065,"askSize":110705,"bidPrice":0.062,"bidSize":16145,"shortable":3,"etf":0,"ttmEps":-0.032226,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.064,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":5.017528416104202,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMC.AU\",,,,,undefined,":{"symbol":"IMC.AU","floatShares":200499327,"roa":"-22.36%","roe":"-52.77%","lyrEps":-0.030443,"volumeRatio":5.017528416104202,"shares":233526869,"dividePrice":0,"high":0.062,"amplitude":0,"preClose":0.064,"low":0.062,"week52Low":0.054,"pbRate":"1.40","psRate":"2.21","week52High":0.11,"institutionHeld":0,"latestPrice":0.062,"committee":-0.745447,"eps":-0.032226,"divideRate":0,"volume":150282,"delay":0,"ttmEps":-0.032226,"open":0.062,"prevYearClose":0.079,"prevWeekClose":0.064,"prevMonthClose":0.067,"prevQuarterClose":0.067,"fiveDayClose":0.067,"twentyDayClose":0.069,"sixtyDayClose":0.082},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMC.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526552825","title":"BRIEF-Immuron Travelan Highest Sales In History","url":"https://stock-news.laohu8.com/highlight/detail?id=2526552825","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526552825?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:23","pubTimestamp":1744323828,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Travelan Highest Sales In HistoryApril 10 (Reuters) - Immuron Ltd IMC.AX:IMMURON TRAVELAN® HIGHEST SALES IN HISTORYSource text: ID:nGNX5BJMtBFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA21C3HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0},{"id":"2526540145","title":"Immuron Travelan® Highest Sales in History","url":"https://stock-news.laohu8.com/highlight/detail?id=2526540145","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526540145?lang=en_us&edition=fundamental","pubTime":"2025-04-11 06:00","pubTimestamp":1744322400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA21C3HM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMC.AU"],"gpt_icon":0},{"id":"2526088903","title":"Immuron Posts Above AU$5 Million Revenue for Nine Months to March, Shares Up 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2526088903","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526088903?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:59","pubTimestamp":1744257542,"startTime":"0","endTime":"0","summary":"Immuron  reported AU$5.3 million sales revenue in the nine months ended March 31, the highest in its history, according to a Thursday Australian bourse filing.The company's March quarter sales were AU$1.3 million, up 2% from last year, of which AU$800,000 was from Australia and AU$500,000 from North America.The company reported an 86% increase in North American sales and a 34% increase in Australia sales, year to date, compared to 2024.The company's shares were up 12% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU"],"gpt_icon":0},{"id":"2526837704","title":"BUZZ-Australia's Immuron gains on highest annual sales for its Travelan drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2526837704","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526837704?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:43","pubTimestamp":1744256624,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immuron gains on highest annual sales for its Travelan drug ** Shares of Immuron IMC.AX rise 11.7% to A$0.067** Stock set for its strongest session since January 14, if current trend holds** The biopharmaceutical co says it has exceeded full-year sales of A$5 million  for its Travelan drug, marking the co's highest annual sales ** About 437,320 shares change hands, 4.2x the 30-day average of 103,595 shares ** Stock down 15.2% YTD, including current session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nL3N3QO0D9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0},{"id":"2517953396","title":"Immuron Secures Exclusive Distribution Deal for Irritable Bowel Syndrome Product; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517953396","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517953396?lang=en_us&edition=fundamental","pubTime":"2025-03-05 10:58","pubTimestamp":1741143496,"startTime":"0","endTime":"0","summary":"Immuron  entered into an exclusive distribution agreement to launch Calmino's ProlBS product in Australia and New Zealand, according to a Wednesday Australian bourse filing.Calmino developed ProIBS for the treatment of symptoms related to irritable bowel syndrome.The collaborative fee-free agreement includes all marketing and sales activities of ProlBS, the filing added.Company shares were down nearly 3% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XAO.AU","BK7508","BK7067","IMC.AU","XKO.AU"],"gpt_icon":0},{"id":"2517107939","title":"BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2517107939","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517107939?lang=en_us&edition=fundamental","pubTime":"2025-03-05 09:10","pubTimestamp":1741137041,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Ltd Announces Exclusive Distribution Agreement For Australia And New Zealand March 5 (Reuters) - Immuron Ltd IMC.AX:EXCLUSIVE DISTRIBUTION AGREEMENT FOR AUSTRALIA AND NEW ZEALAND TO LAUNCH PROIBSFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2517998720","title":"Immuron Ltd - Exclusive Distribution Agreement for Australia and New Zealand to Launch Proibs","url":"https://stock-news.laohu8.com/highlight/detail?id=2517998720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517998720?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:51","pubTimestamp":1741128672,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PN0OE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2504157142","title":"BRIEF-Immuron Travelan® continued strong sales growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2504157142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504157142?lang=en_us&edition=fundamental","pubTime":"2025-01-17 20:53","pubTimestamp":1737118431,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Travelan® continued strong sales growthJan 17 (Reuters) - Immuron Ltd IMC.AX:IMMURON TRAVELAN® CONTINUED STRONG SALES GROWTHSource text: ID:nGNX5K2yv6Further company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nTUA4WMTKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0},{"id":"2504703158","title":"Immuron Travelan® Continued Strong Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2504703158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504703158?lang=en_us&edition=fundamental","pubTime":"2025-01-17 19:00","pubTimestamp":1737111600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250117:nTUA4WMTKG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMC.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2504068909","title":"Immuron's Global Sales for Travelan Surge 249% in December 2024 Quarter; Shares Rise 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2504068909","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504068909?lang=en_us&edition=fundamental","pubTime":"2025-01-17 11:56","pubTimestamp":1737086192,"startTime":"0","endTime":"0","summary":"Immuron  reported global sales for its immune supplement, Travelan, of roughly AU$2.5 million in the December 2024 quarter, a surge of 249% year on year, according to a Friday filing with the Australian bourse.Sales in Australia soared 315% to nearly AU$1.9 million, while North American sales climbed 141% to AU$652,000.Global half-year sales jumped 70% to AU$4 million.The biopharmaceutical company's shares climbed past 8% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU"],"gpt_icon":0},{"id":"2503659098","title":"Immuron Partners With Monash University on Antimicrobial Resistance Research; Shares Down 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503659098","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503659098?lang=en_us&edition=fundamental","pubTime":"2025-01-15 11:11","pubTimestamp":1736910666,"startTime":"0","endTime":"0","summary":"Immuron  partnered with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens, according to a Wednesday filing with the Australian bourse.The collaboration will involve the Biomedicine Discovery Institute research team and make use of the Immuron technology platform, the filing said.The parties will negotiate whether to jointly develop or commercialize the outcomes of the research collaboration on commercially reasonable terms after the results are known, per the filing.Shares fell past 12% in afternoon trade Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2503152691","title":"BRIEF-Immuron Announces Travelan® Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503152691","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503152691?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:38","pubTimestamp":1736854698,"startTime":"0","endTime":"0","summary":"BRIEF-Immuron Announces Travelan® Clinical Trial UpdateJan 14 (Reuters) - Immuron Ltd IMC.AX:IMMURON ANNOUNCES TRAVELAN® CLINICAL TRIAL UPDATESource text: ID:nGNX62sh4YFurther company coverage: IMC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA1RTLMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2503528049","title":"Immuron Announces Travelan® Clinical Trial Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2503528049","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503528049?lang=en_us&edition=fundamental","pubTime":"2025-01-14 19:00","pubTimestamp":1736852400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUA1RTLMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMC.AU"],"gpt_icon":0},{"id":"2503924265","title":"Immuron progresses development of traveller’s diarrhea drug Travelan","url":"https://stock-news.laohu8.com/highlight/detail?id=2503924265","media":"The Market Herald","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503924265?lang=en_us&edition=fundamental","pubTime":"2025-01-14 12:55","pubTimestamp":1736830500,"startTime":"0","endTime":"0","summary":"Immuron Ltd  has moved through a series of development milestones for its drug Travelan: which aims at preventing contraction of traveller’s diarrhea, a disorder of the digestive tract caused by pathogenic bacteria.The company on Tuesday told investors it had submitted a Clinical Study Report to the US Food and Drug Administration  for the recently completed Phase Two study on the drug, aiming to progress to Phase Three once an ‘end of Phase Two’ meeting is arranged.The Phase Two study was a randomised, double-blind, placebo-controlled trial that sought to find out the efficacy of Travelan  in a controlled human infection model for Enterotoxigenic Escherichia Coli .According to the function of Travelan, the drug’s antibodies target and bind to ETEC antigen in the gastrointestinal tract, block LPS epitopes and therefore reduce antigen exposure, resulting in lower overall IgA and IgG antibody titers.The material provided in this article is for information only and should not be treated a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/immuron-progresses-development-of-travellers-diarrhea-drug-travelan-2025-01-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ETEC","IMC.AU","BK7508","BK7067","BK4134"],"gpt_icon":0},{"id":"2503560075","title":"BUZZ-Australia's Immuron rises on positive results for Travelan Phase 2 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2503560075","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503560075?lang=en_us&edition=fundamental","pubTime":"2025-01-14 10:51","pubTimestamp":1736823060,"startTime":"0","endTime":"0","summary":"** Shares of Immuron    rise as much as 16.3% to A$0.10, set for their strongest session since April 10, 2024, if gains hold   ** The biopharmaceutical co hits highest level since early October   ** Co submits clinical study report for its recently completed Phase 2 study of Travelan to the U.S. FDA   ** Travelan is one of co's flagship products aimed at reducing the likelihood of contracting traveler's diarrhoea   ** Study implies that Travelan aids the reduction of pathological diarrhoea-causing bacteria over time   ** About 1.8 mln shares change hands, 28.6 times compared with the 30-day average volume of 63,415 shares   ** Stock rose 2.6% in 2024 ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XKO.AU","XAO.AU","BK7508","XJO.AU","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2489238141","title":"Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th","url":"https://stock-news.laohu8.com/highlight/detail?id=2489238141","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489238141?lang=en_us&edition=fundamental","pubTime":"2024-12-06 21:35","pubTimestamp":1733492100,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 06, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Small Cap Growth Virtual Investor Conference to be held December 5th.Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.“We are looking forward to hosting the Small Cap Growth Virtual Investor Conference which will feature presentations from OTCQX, OTCQB, and exchange-listed companies,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group.“This event will provide issuers with the opportunity to engage a broader investor base.”Virtual Investor Conferences Contact:John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group  220-2221johnv@o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-cap-growth-virtual-investor-133500559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BNAIW","BK4135","NEXNF","QLD","MHGU","EXOD","PSQ","TQQQ","ET","BK4133","BK4581","MNQmain","BK4212","ACCMF","BK4144","OCGPF","QID","BK4136","SQQQ","BK4187","REVVF","BK4139","NQmain","XBOTF","IMC.AU","BNAI","BK4134","BK4588","BK4209","BK4590",".IXIC","IMRN","BK4023","BK4561","BK4585"],"gpt_icon":1},{"id":"2488910666","title":"Small Cap Growth Virtual Investor Conference Agenda Announced for December 5th","url":"https://stock-news.laohu8.com/highlight/detail?id=2488910666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488910666?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:35","pubTimestamp":1733232900,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 03, 2024  -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Small Cap Growth Virtual Investor Conference to be held December 5th.Individual investors, institutional investors, advisors, and analysts are invited to attend.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log in, attend live presentations, or schedule 1x1 meetings with management.“We are looking forward to hosting the Small Cap Growth Virtual Investor Conference, which will feature presentations from OTCQX, OTCQB, and exchange-listed companies,” said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group.“This event will provide issuers with the opportunity to engage a broader investor base.”Virtual Investor Conferences Contact:John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group  220-2221johnv","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pFljWkapktZgUPklKmqXAw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c1bc32f339f4e97512173ec64c4449c0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/small-cap-growth-virtual-investor-133500567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXOD","NQmain","PSQ","BK4144","SQQQ","BK4023","NEXNF","IMC.AU","MHGU","QLD","BK4139","BK4581","ET","BK4134",".IXIC","BK4561","MNQmain","BK4136","IMRN","ACCMF","TQQQ","BK4585","BK4187","BK4135","BK4590","QID","OCGPF","BK4588","BNAI","BK4133","XBOTF","REVVF","BK4212","BNAIW","BK4209"],"gpt_icon":1},{"id":"2475522355","title":"Immuron Travelan® Continued Strong Sales Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2475522355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475522355?lang=en_us&edition=fundamental","pubTime":"2024-10-15 18:00","pubTimestamp":1728986400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUA2Z8BLT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMC.AU","BK7067"],"gpt_icon":0},{"id":"2475585675","title":"Immuron's Travelan Sales Climb 13% in September Quarter; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475585675","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475585675?lang=en_us&edition=fundamental","pubTime":"2024-10-15 12:58","pubTimestamp":1728968297,"startTime":"0","endTime":"0","summary":"Immuron  recorded a 13% quarterly increase in the global sales of its immune supplement, Travelan, in the September quarter, according to a Tuesday filing with the Australian bourse.Sales of Travelan in Australia increased 3% to AU$1 million in the September quarter from AU$983,000 in the three months to June. North American sales climbed 48% to AU$456,000 from AU$309,000 in the June quarter.The biopharmaceutical company's shares were up nearly 4% in recent Tuesday trade.Price : $0.09, Change: $+0.003, Percent Change: +3.66%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMC.AU"],"gpt_icon":0},{"id":"2475532150","title":"BRIEF-Immuron Posts Quarterly Global Sales A$1.5 Million, Up 13% On Prior Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2475532150","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475532150?lang=en_us&edition=fundamental","pubTime":"2024-10-15 08:35","pubTimestamp":1728952520,"startTime":"0","endTime":"0","summary":"Oct 15 (Reuters) - Immuron Ltd   :   * SEPTEMBER 2024 QUARTER GLOBAL SALES A$1.5 MILLION UP 13% ON PRIOR QUARTERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMC.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMC.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2023-02-28","symbol":"IMC.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1677502800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMC.AU\",market:\"AU\",,,undefined,":[]}}